Information Provided By: 
Fly News Breaks for July 28, 2015
SNY, REGN
Jul 28, 2015 | 09:28 EDT
Roth Capital analyst Joseph Pantginis believes Regeneron's (REGN) latest collaboration with Sanofi (SNY) will renew speculation that Sanofi will ultimately purchase Regeneron outright. The third major collaboration between the companies for immuno-oncology assets is "another impressive deal" for Regeneron's discovery platform, Pantginis tells investors in a research note. He keeps a Neutral rating on the stock with a $495 price target. Shares of Regeneron are up $14.46 to $554.49 in pre-open trading.
News For REGN;SNY From the Last 2 Days
REGN
Apr 24, 2024 | 07:20 EDT
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
Apr 22, 2024 | 11:36 EDT
